High content screening (HCS) is widely used in drug discovery and cell biology in life sciences research. Currently, high content screening is widely used for primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. In this article, we will take a look at the commercial viability and future growth of these applications.
High Content Screening in Primary & Secondary Screening
High content screening is an effective mechanism of processing cells at early stages of the drug discovery process. Innovation in HCS technology has meant that it is now being used for primary as well as secondary screening. This is especially true in case of diseases with unknown causative molecular targets.
Pharmaceutical companies around the world are more focused on assaying project-related, compound libraries. Owing to these changes, application of high content screening in primary and secondary screening is anticipated to witness a steady increase. Use of HCS in primary and secondary screen is anticipated to acquire a market share of 36.6% by 2025.
High Content Screening in Target Identification & Validation
HCS has proved to be highly successful in identify new components of cells and validating their functionalities. Target identification and validation provides a base through which molecules that interfere with disease can be identified. High content screening has the advantage of providing spatial information about cells during the target identification and validation process. Use of high content screening for target identification and validation is estimated to reach US$ 563 Mn by 2025.
High Content Screening in Toxicity Studies
High content screening allows researchers to analyse the behaviour of multiple cells and measure their response to environmental and chemical stimuli. Although HCS has gained reliability in the field of cytotoxicity, however evaluation of cells beyond this remains a key opportunity for HCS globally. Toxicity studies using high content screening, as an application segment, was worth US$ 205.2 Mn in 2015, and according to a research report by Future Market Insights, this segment will witness a compound annual growth rate of 6.3% till 2025.
High Content Screening in Compound Profiling
The use of high content screening in compound profiling is anticipated to grow in the near future. HCS offers researchers numerous advantages in compound profiling over traditional image-based assays. It is anticipated that the market value of compound profiling segment will be to the tune of US$ 240.5 Mn.
Key Trends in High Content Screening Sector
Secondary screening is gaining focus among researchers and pharmaceutical companies. Growing concerns related to toxicity studies and emphasis on providing solutions in hepatoxicity is expected to increase the demand for HCS instruments in the near future.
Development of value-added applications has emerged as a key trend in the high content screening industry, with only a select few pharmaceutical companies developing a specific product line for life sciences.
High price of HCS instruments drives the demand for other image analysis instruments, such as flow cytometers. However, innovation in the field of manufacturing technology and reduction in the price of HCS components is expected to bring down the prices in the near future.
The positive impact of high content screening instruments on toxicity studies has resulted in increased adoption of this technology by pharmaceutical companies. For example, Genedata AG’s 75% image analysis and management software customers are pharmaceutical companies.
Increase in the development of automated systems to analyse cell separation and scalability is currently being witnessed in the sector. Demand for efficient purification protocols is expected to boost the demand for high content screening instruments in the future.
Browse Full "High Content Screening (HCS) Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025" Market Research Report at http://www.futuremarketinsights.com/reports/details/high-content-screening-market
The AI-Assisted Clinical Trial Protocol Design Market is segmented by Technology (Protocol Feasibility AI, Eligibility Criteria Optimization, Patient Burden Modeling, Site Selection Analytics, Regulatory Document Assistants), Trial Phase, Service Model, End Use, Buyer Type, and Region. Forecast for 2026 to 2036.
Insulin Aspart Market is segmented by Product type, delivery format, indication, distribution channel and region. Forecast for 2026 to 2036.
The facial injectables market is segmented by product type, application, end user, distribution channel and region. Forecast for 2026 to 2036.
The pet light therapy devices market is segmented by Product Type, Light Source, Application, Animal Type, End User, Distribution Channel, and Region. Forecast for 2026 to 2036.
The Multi-Surface Disinfection Booster Systems with Low QAC Load Market is segmented by Booster Type (Surfactant Synergists, Oxidizer Boosters, Acid Boosters, Enzyme Boosters, Chelant Boosters), Disinfectant Compatibility (Low QAC Systems, Peroxide Systems, Organic Acid Systems, Alcohol Assisted Systems, Chlorine Free Systems), Formulation Mode (Liquid Concentrates, Ready Boosters, Dosing Cartridges, Tablet Packs, Pump Systems), Surface Coverage (Hard Nonporous, Food Contact, Soft Surface, Floor Care, Equipment Surface), End Use (Healthcare Facilities, Hospitality Sites, Foodservice Sites, Schools, Household Care, Offices), and Sales Channel (Direct Supply, Distributors, Retail Stores, Online Stores, Contract Cleaners). Forecast for 2026 to 2036.
